Abstract
Background
Bone giant cell tumors, although benign, may be locally aggressive and cause severe morbidity; in some cases, they can also disseminate at distance and cause death. Denosumab has been approved to treat unresectable bone giant cell tumors or when surgery is likely to result in severe morbidity. Furthermore, its curative potential has been recently suggested.
Case
An 18-year-old girl presented with a spinal giant cell tumor at T9. Neo-adjuvant denosumab was administered for 9 months with great clinical and analytical tolerance. A posterior left T9 costo-transversectomy and vertebral body curettage was performed and the spine stabilized. Interestingly, histopathology examination of the surgical specimens found no evidence of tumoral cells. Denosumab was reinstated until completion of 12 months of treatment.
Conclusion
Denosumab has an important but still limited role in the treatment of spinal giant cell tumors. Here, it resulted in complete histological resolution of the tumor, potentially widening its applicability from a strictly neo-adjuvant to a curative role.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Heck R Jr, Toy P (2017) Benign/aggressive tumors of bone. In: Azar FMM, Beaty JH, Canale ST (eds) Campbell’s operative orthopaedics, 13th edn. Elsevier, Philadelphia, pp 923–944.e3
Boriani S, Bandiera S, Casadei R et al (2012) Giant cell tumor of the mobile spine: a review of 49 cases. Spine (Phila Pa 1976) 37:E37–E45. https://doi.org/10.1097/brs.0b013e3182233ccd
Redhu R, Poonia R (2012) Giant cell tumor of dorsal vertebral body. J Craniovertebr Junction Spine 3:67–69. https://doi.org/10.4103/0974-8237.116542
Knochentumoren A, Becker WT, Dohle J et al (2008) Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Jt Surg-Am 90:1060–1067. https://doi.org/10.2106/JBJS.D.02771
Luksanapruksa P, Buchowski JM, Singhatanadgige W et al (2016) Management of spinal giant cell tumors. Spine J 16:259–269. https://doi.org/10.1016/j.spinee.2015.10.045
Brien EW, Mirra JM, Kessler S et al (1997) Benign giant cell tumor of bone with osteosarcomatous transformation (“dedifferentiated” primary malignant GCT): report of two cases. Skeletal Radiol 26:246–255. https://doi.org/10.1007/s002560050230
Caudell JJ, Ballo MT, Zagars GK et al (2003) Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 57:158–165. https://doi.org/10.1016/s0360-3016(03)00416-4
Lin PP, Guzel VB, Moura MF et al (2002) Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer 95:1317–1325. https://doi.org/10.1002/cncr.10803
Branstetter DG, Nelson SD, Manivel JC et al (2012) Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 18:4415–4424. https://doi.org/10.1158/1078-0432.CCR-12-0578
Luksanapruksa P, Buchowski JM, Singhatanadgige W, Bumpass DB (2016) Systematic review and meta-analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine. Glob Spine J 6:798–803. https://doi.org/10.1055/s-0036-1579746
Rutkowski P, Gaston L, Borkowska A et al (2018) Denosumab treatment of inoperable or locally advanced giant cell tumor of bone—multicenter analysis outside clinical trial. Eur J Surg Oncol 44:1384–1390. https://doi.org/10.1016/j.ejso.2018.03.020
Kumar R, Meis JM, Amini B et al (2017) Giant cell tumor of cervical spine presenting as acute asphyxia. Spine (Phila Pa 1976) 42:E629–E632. https://doi.org/10.1097/brs.0000000000001951
Goldschlager T, Dea N, Boyd M et al (2015) Giant cell tumors of the spine: has denosumab changed the treatment paradigm? J Neurosurg Spine 22:526–533. https://doi.org/10.3171/2014.10.SPINE13937
Mattei TA, Ramos E, Rehman AA et al (2014) Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab. Spine J 14:e15–e21. https://doi.org/10.1016/j.spinee.2014.02.019
Charest-Morin R, Boriani S, Fisher CG et al (2016) Benign tumors of the spine: has new chemotherapy and interventional radiology changed the treatment paradigm? Spine (Phila Pa 1976) 41(Suppl 2):S178–S185. https://doi.org/10.1097/brs.0000000000001818
Law GW, Yeo NEM, Sen Howe T et al (2018) Recommencement of denosumab for unresectable giant cell tumor of the cervical spine. Spine (Phila Pa 1976) 43:E551–E556. https://doi.org/10.1097/brs.0000000000002440
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest in relation to this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xará-Leite, F., Coutinho, L., Fleming, C. et al. Can Denosumab cure giant cell tumors of the spine? A case report and literature review. Eur J Orthop Surg Traumatol 30, 19–23 (2020). https://doi.org/10.1007/s00590-019-02554-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00590-019-02554-9